On Tuesday 18th September at the Meon Valley Golf & Country Club, they will compete for the ‘alternative’ Ryder Cup and the opportunity to raise money for Complete FS’s charity of the year, Cancer Research.
Complete FS Director, Tony Salentino, said: “ It is time to take the gloves off and settle the bragging rights between the ‘Old World’ mortgage community representing Europe and the vibrant “ New World’ bridging sector, representing our brash cousins across the water. I am captaining the ‘European’ Mortgage Team and my colleague, Phil Jay, will captain the ‘US’ Bridging Team."
GE Money, Kent Reliance, Buckinghamshire Building Society, Blemain Group, Bath Building Society and Platform Homeloans will represent the Mortgage Team, while the Bridging Team is made up of representatives from Omni Capital, Precise Bridging, United Trust Bank and Lancashire Mortgage Corporation.
Salentino added: “It has been clear for some time that the mortgage market has had its nose put out of joint by the recent successes of the bridging upstarts and this gives my Mortgage team the chance to really spank the yanks!”
Opposing team captain Phil Jay replied: “ Bridging might be the underdog in terms of volumes but we are easily the most proactive and colourful sector in the lending market and we aim to wipe those complacent smiles off the faces of the Mortgage team.”
It is rumoured that heavyweights from both the Mortgage and Bridging golf tours will be making an appearance with the possibility of Colin ‘Shock and Awe’ Sanders, fresh from topping the Bridging Tour averages and his opposite number from the Mortgage Tour, Nick ‘Never say Die’ Jones both appearing to settle top dog status by going head to head in the afternoon singles.
Recent form has seen the European team bossing the official Ryder Cup but the USA has a strong team for the main event this year and at Meon Valley, the rivalry will be just as intense and the result too close to call with the losers taking not only the wooden spoon, but also making a substantial donation to Cancer Research.
